Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02198170 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02198170 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 18 participants.
The verdict
NCT02198170, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the influence of simultaneous CYP3A4 and p-glycoprotein inhibition on lenvatinib pharmacokinetics following a single oral dose of 5 mg lenvatinib.
Interventions
- DRUG ketoconazole-placebo
- DRUG placebo-ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02198170
The ClinicalTrials.gov registry entry for NCT02198170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ketoconazole-placebo is the first listed.
NCT02198170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02198170 about?
NCT02198170 is a clinical study titled "A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers". The purpose of this study is to assess the influence of simultaneous CYP3A4 and p-glycoprotein inhibition on lenvatinib pharmacokinetics following a single oral dose of 5 mg lenvatinib.
What is the current status of trial NCT02198170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-02. Estimated completion is 2011-06.
What interventions are being tested in trial NCT02198170?
The interventions under investigation include: ketoconazole-placebo (DRUG), placebo-ketoconazole (DRUG).
Who is sponsoring clinical trial NCT02198170?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.